Biomarker Discovery Made Smarter

We offer comprehensive genomic profiling (CGP) using next-generation sequencing (NGS) to support precision oncology clinical development programs. Our PanCancerIQ™ assay delivers deep insights into tumor biology from both FFPE tissue and liquid biopsies, helping accelerate biomarker-driven research and clinical trial success.

pancancer-iq

What Is PanCancerIQ™?

PanCancerIQ™ is a robust NGS-based assay powered by the Illumina TruSight Oncology 500 (TSO500) platform and enhanced by clinical interpretation through a knowledgebase developed by MD Anderson Cancer Center in partnership with Philips.

This assay identifies key genomic alterations that drive cancer progression and treatment response, including:

  • Mutations, indels, and copy number variations (CNVs)

  • RNA-based gene fusions

  • Microsatellite instability (MSI)

  • Tumor mutational burden (TMB)

cancer-tumor-cells

Applications & Benefits

PanCancerIQ™ supports a wide range of clinical and translational research goals:

  • Patient screening and cohort stratification

  • Biomarker-driven trial optimization

  • Targeted therapy efficacy assessment

  • Precision oncology implementation

  • Drug development decision-making

Our consultative approach and integrated genomic solutions help you interrogate the oncogenome with unparalleled breadth and sensitivity, enabling faster, more informed decisions.

liquid-biopsy

FFPE & Liquid Biopsy Capabilities

Validated for both formalin-fixed paraffin-embedded (FFPE) tissue and plasma-based liquid biopsies, PanCancerIQ™ offers:

  • Non-invasive mutation detection via circulating tumor DNA (ctDNA)

  • High concordance of variant allele frequency (VAF) between matched FFPE and plasma samples

  • Rapid turnaround and improved detection limits